10月9日，和元生物涨4.19%，成交额2.85亿元。两融数据显示，当日和元生物获融资买入额2519.41万 元，融资偿还2792.02万元，融资净买入-272.62万元。截至10月9日，和元生物融资融券余额合计1.53亿 元。 截至6月30日，和元生物股东户数1.26万，较上期增加6.83%；人均流通股50864股，较上期减少6.39%。 2025年1月-6月，和元生物实现营业收入1.20亿元，同比增长6.01%；归母净利润-1.05亿元，同比增长 7.74%。 责任编辑：小浪快报 融资方面，和元生物当日融资买入2519.41万元。当前融资余额1.53亿元，占流通市值的2.90%，融资余 额低于近一年50%分位水平，处于较低位。 融券方面，和元生物10月9日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，超过近一年80%分位水平，处于高位。 资料显示，和元生物技术(上海)股份有限公司位于上海市浦东新区紫萍路908弄19号楼，成立日期2013 年3月5日，上市日期2022年3月22日，公司主营业务涉及为基因治疗的基础研究提供基因治疗载体研 ...

证券之星消息，10月9日医疗服务板块较上一交易日上涨0.91%，九洲药业领涨。当日上证指数报收于 3933.97，上涨1.32%。深证成指报收于13725.56，上涨1.47%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 603456 | 九洲药业 | 20.61 | 5.96% | 41.88万 | | 8.44亿 | | 002044 | 美年健康 | 5.20 | 4.63% | 166.72万 | | · 8.71亿 | | 688238 | 和元生物 | 8.20 | 4.19% | 34.45万 | | 2.85亿 | | 301293 | 三博脑科 | 60.80 | 4.02% | 11.01万 | | 6.60亿 | | 688131 | 皓元医药 | 85.48 | 3.49% | 5.98万 | | 5.08亿 | | 300015 | 爰尔眼科 | 12.77 | 3.48% | 129.82万 | | 16.31亿 | ...

责任编辑：小浪快报 资料显示，和元生物技术(上海)股份有限公司位于上海市浦东新区紫萍路908弄19号楼，成立日期2013 年3月5日，上市日期2022年3月22日，公司主营业务涉及为基因治疗的基础研究提供基因治疗载体研 制、基因功能研究等CRO服务,以及为基因药物的研发提供IND-CMC药学研究、临床样品GMP生产等 CDMO服务。主营业务收入构成为：细胞和基因治疗CDMO服务54.75%，细胞和基因治疗CRO服务 33.96%，生物制剂、试剂及其他10.28%，再生医学服务1.02%。 截至6月30日，和元生物股东户数1.26万，较上期增加6.83%；人均流通股50864股，较上期减少6.39%。 2025年1月-6月，和元生物实现营业收入1.20亿元，同比增长6.01%；归母净利润-1.05亿元，同比增长 7.74%。 9月25日，和元生物跌1.84%，成交额1.67亿元。两融数据显示，当日和元生物获融资买入额1909.92万 元，融资偿还2313.76万元，融资净买入-403.83万元。截至9月25日，和元生物融资融券余额合计1.44亿 元。 融资方面，和元生物当日融资买入1909.92万元。当前融资余 ...

Market Performance - On September 22, the medical services sector rose by 0.18% compared to the previous trading day, with Haoyuan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3828.58, up 0.22%, while the Shenzhen Component Index closed at 13157.97, up 0.67% [1] Top Gainers in Medical Services - Haoyuan Pharmaceutical (688131) closed at 79.32, up 7.49% with a trading volume of 76,500 shares and a transaction value of 592 million [1] - Bid Pharma (688073) closed at 73.78, up 5.52% with a trading volume of 14,500 shares and a transaction value of 104 million [1] - Heyuan Biotechnology (688238) closed at 8.10, up 3.98% with a trading volume of 218,700 shares and a transaction value of 174 million [1] Top Losers in Medical Services - Pulangsi (301257) closed at 49.10, down 4.21% with a trading volume of 43,300 shares and a transaction value of 216 million [2] - Innovative Medical (002173) closed at 21.53, down 4.18% with a trading volume of 612,900 shares and a transaction value of 134 million [2] - ST Zhongzhu (600568) closed at 2.02, down 3.81% with a trading volume of 226,400 shares and a transaction value of 46 million [2] Capital Flow in Medical Services - On the same day, the medical services sector experienced a net outflow of 643 million from institutional investors, while retail investors saw a net inflow of 438 million [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - For WuXi AppTec (603259), the net inflow from institutional investors was 27.8 million, while retail investors had a net outflow of 29.7 million [3] - Haoyuan Pharmaceutical (688131) saw a net inflow of 17.6 million from institutional investors but a net outflow of 13.9 million from retail investors [3] - Bid Pharma (688073) had a minimal net inflow of 120,000 from institutional investors, with retail investors experiencing a net outflow of 768,640 [3]

Group 1 - The private economy in Shanghai plays a crucial role, contributing nearly 30% of the city's industrial output and fixed asset investment, and accounting for three-quarters of new employment in 2024 [1] - Shanghai is home to 80% of the "specialized, refined, distinctive, and innovative" enterprises, as well as "little giant" companies, which are predominantly private enterprises [1] - The success of Black Lake Technology is attributed to breakthroughs in AI empowerment and equipment adaptability, enabling quality cultural and artistic resources to reach global markets without physical space limitations [3][4] Group 2 - Black Lake Technology has assisted over 30,000 factories in digital transformation, becoming the leading industrial software provider in the Asia-Pacific region [4] - The founder of Black Lake Technology noted that the digital transformation wave has led more enterprises to recognize the importance of digital solutions, which is a market opportunity for the company [4] - The establishment of Union Medical, which focuses on high-end medical equipment, has shifted the reliance on imported brands to domestic production, with products now in over 15,000 clinical and research institutions globally [6][8] Group 3 - Union Medical has formed deep collaborations with universities and hospitals, enhancing its innovation capabilities through industry-academia integration [8] - The company has cultivated nearly 1,000 quality domestic suppliers, including around 100 "specialized, refined, distinctive, and innovative" enterprises, contributing to the capital market [8] - The logistics technology company, Westwell Technology, has expanded its services from single logistics scenarios to multi-modal transport across 28 countries, emphasizing the importance of AI and application scenarios for product iteration [10]

Core Insights - The article discusses the successful completion of the "Pudong Science and Technology Innovation - Haiwang Summit (Phase II) CEO Training Camp," which gathered over thirty technology entrepreneurs in Shanghai for a two-day learning experience [3][10] - The training focused on strategic management and product development, providing practical insights and frameworks for entrepreneurs to navigate complex environments and achieve sustainable growth [3][4] Group 1: Strategic Management - Expert Chen Zhuyou emphasized the importance of forward-thinking strategic thinking for long-term development in a complex environment, highlighting the need for multi-layered analysis of macro, meso, and micro environments [4][5] - He discussed the limitations of homogeneous competition and advocated for differentiation, specialization, and cognitive competition to gain a competitive edge [4] - The course provided strategic tools and frameworks to help entrepreneurs enhance competitiveness during the transition from old to new growth drivers [4][6] Group 2: Product Development - Zhang Shanfeng, Chairman of Guokewanhua, focused on key aspects of product development management for startups, stressing the importance of engineering and user orientation for product success [5][6] - He highlighted the need for clear product hierarchy and business models, focusing on core users and standardizing product documentation as essential steps for startups to mature [5][6] - The value of AI in improving research efficiency and optimizing documentation and processes was also emphasized, along with the importance of data security and private deployment [6] Group 3: Practical Experience - The training included a visit to He Yuan Biotechnology (Shanghai) Co., Ltd., a high-tech enterprise listed on the Sci-Tech Innovation Board, which specializes in cell and gene therapy [8][10] - Xu Luyuan, Deputy General Manager and Board Secretary of He Yuan Biotechnology, provided insights into the company's development history, core technological capabilities, and practical advice for startups facing challenges in development and technology transfer [10] - The visit allowed participants to gain a more intuitive understanding of industry innovation models and operational management through direct interaction [10]

【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不 对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担 全部责任。邮箱：news_center@staff.hexun.com 格隆汇9月1日丨和元生物(688238.SH)公布，公司于近日收到股东华睿盛银及其一致行动人出具的《关 于股份减持计划实施结果的告知函》，截至2025年8月29日，股东华睿盛银及其一致行动人通过集中竞 价交易方式合计减持公司股份数量6,483,392股，占公司总股本的0.9989%。股东华睿盛银及其一致行动 人本次减持计划时间区间届满，本次减持计划已实施完毕。 ...

证券代码：688238 证券简称：和元生物 公告编号：2025-060 和元生物技术（上海）股份有限公司 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 露了《和元生物技术（上海）股份有限公司简式权益变动报告书》及《关于持股 次权益变动后，华睿盛银及其一致行动人持股比例降至 5%以下，不再是公司持 股 5%以上股东。 划实施结果的告知函》，截至 2025 年 8 月 29 日，股东华睿盛银及其一致行动人 通过集中竞价交易方式合计减持公司股份数量 6,483,392 股，占公司总股本的 计划已实施完毕。 ? 大股东持股的基本情况 本次减持计划实施前，和元生物技术（上海）股份有限公司（以下简称"公 司"股东浙江华睿盛银创业投资有限公司（以下简称"华睿盛银"）持有公司股 份 19,672,145 股，占公司总股本的比例为 3.0310%；诸暨富华产业转型升级基 金合伙企业（有限合伙） （以下简称"诸暨富华"）持有公司股份 7,052,900 股， 占公司总股本的比例为 1.0867%；浙江华睿胡庆余堂 ...

证券代码：688238 证券简称：和元生物 公告编号：2025-060 和元生物技术（上海）股份有限公司 股东减持股份计划时间届满暨减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，和元生物技术（上海）股份有限公司（以下简称"公 司"股东浙江华睿盛银创业投资有限公司（以下简称"华睿盛银"）持有公司股 份 19,672,145 股，占公司总股本的比例为 3.0310%；诸暨富华产业转型升级基 金合伙企业（有限合伙）（以下简称"诸暨富华"）持有公司股份 7,052,900 股， 占公司总股本的比例为 1.0867%；浙江华睿胡庆余堂健康产业投资基金合伙企业 （有限合伙）（以下简称"华睿胡庆余堂"）持有公司股份 4,614,693 股，占公 司总股本的比例为 0.7110%；浙江华睿火炬创业投资合伙企业（有限合伙）（以 下简称"华睿火炬"）持有公司股份 3,916,087 股，占公司总股本的比例为 0.6034%； 杭州华睿嘉银股权投资合伙企业 ...

格隆汇9月1日丨和元生物(688238.SH)公布，公司于近日收到股东华睿盛银及其一致行动人出具的《关 于股份减持计划实施结果的告知函》，截至2025年8月29日，股东华睿盛银及其一致行动人通过集中竞 价交易方式合计减持公司股份数量6,483,392股，占公司总股本的0.9989%。股东华睿盛银及其一致行动 人本次减持计划时间区间届满，本次减持计划已实施完毕。 ...